Cargando…

Combination of synbiotic and sitagliptin in nonalcoholic fatty liver disease: Is it better than sitagliptin alone?

Detalles Bibliográficos
Autor principal:	Cho, Yong Kyun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Association for the Study of the Liver 2018
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6166103/ https://www.ncbi.nlm.nih.gov/pubmed/30196651 http://dx.doi.org/10.3350/cmh.2018.1006

Ejemplares similares

Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease
por: Sayari, Saba, et al.
Publicado: (2018)

The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone
por: Ohki, Takamasa, et al.
Publicado: (2012)

Sitagliptin, sitagliptin and metformin, or sitagliptin and amitriptyline attenuate streptozotocin-nicotinamide induced diabetic neuropathy in rats
por: Sharma, Ashish Kumar, et al.
Publicado: (2012)

Effects of quercetin, sitagliptin alone or in combination in testicular toxicity induced by doxorubicin in rats
por: Ahmed, Zheen Aorahman, et al.
Publicado: (2019)

The Effect of Sitagliptin on Lipid Metabolism of Fatty Liver Mice and Related Mechanisms
por: Xu, Bilin, et al.
Publicado: (2017)

Sitagliptin-induced hemolysis
por: Bekur, Ragini, et al.
Publicado: (2010)

Sitagliptin-Associated Angioedema
por: Gosmanov, Aidar R., et al.
Publicado: (2012)

The therapeutic effects of berberine plus sitagliptin in a rat model of fatty liver disease
por: Mehrdoost, Soraya, et al.
Publicado: (2021)

Effects of sitagliptin on intrahepatic lipid content in patients with non-alcoholic fatty liver disease
por: Wang, Xingchun, et al.
Publicado: (2022)

Effect of sitagliptin on proteinuria in patients with type 2 diabetes – A renoprotective effect of sitagliptin
por: Narimani, Rouhollah, et al.
Publicado: (2021)

Sitagliptin-induced pancreatitis – a longer road than expected
por: Nelson, Matthew, et al.
Publicado: (2014)

Fixed drug eruption to sitagliptin
por: Gupta, Mrinal, et al.
Publicado: (2015)

Effects of Sitagliptin on Insulin and Glucagon Levels in Type 2 Diabetes Mellitus
por: Kim, Ji Hyun
Publicado: (2015)

Comparison of the efficacy of sitagliptin and glimepiride dose‐up in Japanese patients with type 2 diabetes poorly controlled by sitagliptin and glimepiride in combination
por: Shimoda, Seiya, et al.
Publicado: (2013)

Bioequivalence Evaluation in Healthy Volunteers: New Generic Formulations of Sitagliptin and Sitagliptin–Metformin Fixed-Dose Combination Compared with the Originator Products
por: Schnaars, Yvonne, et al.
Publicado: (2022)

Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
por: Yan, Jinhua, et al.
Publicado: (2019)

Potential Therapeutic Benefits of Metformin Alone and in Combination with Sitagliptin in the Management of Type 2 Diabetes Patients with COVID-19
por: Al-Kuraishy, Hayder M., et al.
Publicado: (2022)

Hepatoprotective effect of sitagliptin against methotrexate induced liver toxicity
por: Abo-Haded, Hany M., et al.
Publicado: (2017)

Unresponsive Intractable Chronic Headache With Sitagliptin
por: Zaghloul, Ahmed, et al.
Publicado: (2018)

Sitagliptin: Is It Effective in Routine Clinical Practice?
por: Mohan Dallumal, Rita, et al.
Publicado: (2015)

Pancreatic Safety of Sitagliptin in the TECOS Study
por: Buse, John B., et al.
Publicado: (2017)

Is sitagliptin effective for the treatment of COVID-19?
por: Memiş, Hasan, et al.
Publicado: (2022)

New combination treatments in the management of diabetes: focus on sitagliptin – metformin
por: Green, Jennifer, et al.
Publicado: (2008)

Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus
por: Miller, Shannon A, et al.
Publicado: (2009)

Call for Comparative Effectiveness Research: Lowering A1c with Sitagliptin, Saxagliptin, or Cinnamon
por: Fairman, Kathleen A., et al.
Publicado: (2009)

Spectroflourometric and Spectrophotometric Methods for the Determination of Sitagliptin in Binary Mixture with Metformin and Ternary Mixture with Metformin and Sitagliptin Alkaline Degradation Product
por: El-Bagary, Ramzia I., et al.
Publicado: (2011)

Nonalcoholic Fatty Liver Disease
por: Filipović, Branka, et al.
Publicado: (2018)

Practical Asymmetric Synthesis of Sitagliptin Phosphate Monohydrate
por: Gao, Haoling, et al.
Publicado: (2018)

Rhinorrhea, cough and fatigue in patients taking sitagliptin
por: Baraniuk, James N, et al.
Publicado: (2010)

Hypoglycemia associated with off-label sitagliptin use
por: Whitley, Heather P, et al.
Publicado: (2008)

Noncardiac Pulmonary Edema induced by Sitagliptin Treatment
por: Belice, Tahir, et al.
Publicado: (2014)

Sitagliptin and Simvastatin Interaction Causing Rhabdomyolysis and AKI
por: Patel, Chinmay, et al.
Publicado: (2019)

Stability of extemporaneously prepared sitagliptin phosphate solution
por: Zaid, Abdel Naser, et al.
Publicado: (2022)

Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes
por: Reynolds, Jonathan K
Publicado: (2009)

Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin
por: Steinberg, Helmut, et al.
Publicado: (2013)

Identification of sitagliptin binding proteins by affinity purification mass spectrometry: Sitagliptin binding proteins identified by affinity purification mass spectrometry
por: Wang, Xue-Ning, et al.
Publicado: (2022)

Effects of metformin, acarbose, and sitagliptin monotherapy on gut microbiota in Zucker diabetic fatty rats
por: Zhang, Minchun, et al.
Publicado: (2019)

Diabetes and Nonalcoholic Fatty Liver Disease
por: Kantartzis, Konstantinos, et al.
Publicado: (2012)

Sitagliptin Is More Effective Than Gliclazide in Preventing Pro-Fibrotic and Pro-Inflammatory Changes in a Rodent Model of Diet-Induced Non-Alcoholic Fatty Liver Disease
por: Ren, Jing, et al.
Publicado: (2022)

Noninvasive Markers for the Diagnosis of Nonalcoholic Fatty Liver Disease
por: Kim, Sang Yong
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_3ng3ruf9ce4k5h2mqo7e218lot